Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma.

about

Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma.

Item

http://www.wikidata.org/entity/Q52838661

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Dose-escalation study evaluati ...... ith cutaneous T-cell lymphoma.

@en

Dose-escalation study evaluati ...... ith cutaneous T-cell lymphoma.

@nl

type

Item

label

Dose-escalation study evaluati ...... ith cutaneous T-cell lymphoma.

@en

Dose-escalation study evaluati ...... ith cutaneous T-cell lymphoma.

@nl

prefLabel

Dose-escalation study evaluati ...... ith cutaneous T-cell lymphoma.

@en

Dose-escalation study evaluati ...... ith cutaneous T-cell lymphoma.

@nl

P1476

Dose-escalation study evaluati ...... ith cutaneous T-cell lymphoma.

@en

P2093

A Hinke

http://www.w3.org/2001/XMLSchema#string

A Tsianakas

http://www.w3.org/2001/XMLSchema#string

D Nashan

http://www.w3.org/2001/XMLSchema#string

M Schiller

http://www.w3.org/2001/XMLSchema#string

R Dummer

http://www.w3.org/2001/XMLSchema#string

R Stadler

http://www.w3.org/2001/XMLSchema#string

W Sterry

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma

Side effects of interferon-alpha therapy

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.

Neuropsychiatric side effects of interferon-alfa therapy.

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

The human 2',5'-oligoadenylate synthetase family: interferon-induced proteins with unique enzymatic properties.

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities.

P304

1841-1847

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JDV.14366

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28557110

http://www.w3.org/2001/XMLSchema#string